On 2026-10-06, RBC Capital raised its JNJ price target to $290.
RBC Capital 于 2026-10-06 将 JNJ 目标价上调至 $290。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
BofA Securities raises JNJ target to $278BofA Securities 上调目标价 强生 (JNJ) 至 $278
Rating Change · September 29, 2026评级变动 · 2026/9/29
HSBC raises JNJ target to $320 from $290HSBC 上调目标价 强生 (JNJ)：$290 → $320
Rating Change · September 10, 2026评级变动 · 2026/9/10
JNJ regulatory decision: FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsJohnson & Johnson（JNJ）的 产品 获美国 FDA 许可或批准
Material Company Event · August 24, 2026公司公告 · 2026/8/24
